DOI: 10.4244/EIJV11SWA24

The Medtronic transcatheter mitral valve implantation system

Nicolo Piazza1*, MD, PhD; Hendrik Treede2, MD; Neil Moat3, MD; Paul Sorajja4, MD; Jeff Popma5, MD; Eberhard Grube6, MD; Steve Bolling7, MD; David Adams8, MD

Device description

Name and manufacturer: Medtronic transcatheter mitral valve; Medtronic, Minneapolis, MN, USA.

Approval status: Preclinical.

Platform: Nitinol.

Specific design: Self-expanding nitinol frame consisting of an inflow (“atrial portion”) and outflow (“ventricular portion”) with support arms securing the position of the device (Figure 1).

Figure 1. The Medtronic transcatheter mitral valve. The valve has a large inflow (“atrial portion”) to help seal and prevent paravalvular mitral regurgitation. The outflow (“ventricular portion”) is short and designed to avoid left ventricular outflow tract obstruction. Two diametric support arms function to capture the A2 and P2 segments of the mitral valve leaflets.

Delivery approach: Transatrial.

Device sizes/length: Not specified.

Procedural details

The current device is delivered via the transatrial approach using a right lateral minithoracotomy, similar to minimally invasive surgical mitral valve repair. The transatrial approach is intended to avoid trauma to the left ventricle, which is a possible risk associated with the transapical approach. The delivery system is inserted into the left atrium at Waterston’s groove and advanced antegradely across the mitral valve into the left ventricle. The two diametric support arms are oriented towards the anterior and posterior mitral valve leaflets. Under fluoroscopic and echocardiographic guidance, the support arms are exposed below the tips of the mitral valve leaflets. The delivery system is retracted slightly in order for the support arms to engage and capture the A2 and P2 segments of the mitral valve leaflets. After entrainment of the mitral valve leaflets, the outflow (“ventricular”) and inflow (“atrial”) portions of the valve are deployed sequentially. Valve position and function are evaluated by angiography and echocardiography. In cases of malpositioning, for example, the device can be fully recaptured and retrieved from the body prior to full release from the delivery catheter.

Clinical data

There are no clinical data as yet available.

Ongoing studies

Acute animal studies have established the safety and feasibility of the procedure. These studies have confirmed the device can maintain an accurate position during deployment and maintain a stable position after its release. Furthermore, there was absence of paravalvular regurgitation, left ventricular outflow tract obstruction and significant transvalvular gradients in the vast majority of animal experiments. Post-mortem examinations have ruled out injury to the mitral valve leaflets or their apparatus after recapturing the device. Chronic animal studies are ongoing.

Unique features

Evidently, bail-out options surrounding transcatheter mitral valve replacement are potentially more challenging than those associated with transcatheter aortic valve replacement. The Medtronic mitral transcatheter valve system is recapturable and retrievable after complete deployment and assessment of valve function. This may avoid the need for bail-out surgery in cases of significant paravalvular mitral regurgitation, left ventricular outflow tract obstruction or device malpositioning.

Potential improvements

A transseptal system is currently in development.

Conflict of interest statement

N. Piazza is a member of the Scientific Advisory Board of Medtronic and a consultant and equity shareholder with HighLife. H. Treede is a member of the Scientific Advisory Board and a Proctor with Medtronic and a consultant with HighLife. N. Moat is a member of the Scientific Advisory Board of Medtronic and a consultant with Tendyne. P. Sorajja is a member of the Scientific Advisory Board of Medtronic and a consultant with Abbott MitraClip. J. Popma, E. Grube, S. Bolling and D. Adams are all members of the Scientific Advisory Board of Medtronic.

Volume 11 Supplement W
Sep 17, 2015
Volume 11 Supplement W
View full issue


Key metrics

On the same subject

10.4244/EIJV11SWA26 Sep 17, 2015
The Sino Medical AccuFit transcatheter mitral valve implantation system
Abdelghani M et al
free

10.4244/EIJV11SWA25 Sep 17, 2015
The HighLife transcatheter mitral valve implantation system
Lange R and Piazza N
free

MITRAL VALVE INTERVENTIONS

10.4244/EIJV12SYA19 Sep 18, 2016
Transcatheter mitral valve implantation: CardiAQ
Barbanti M and Tamburino C
free

10.4244/EIJV11SWA23 Sep 17, 2015
The Tendyne transcatheter mitral valve implantation system
Perpetua E and Reisman M
free

MITRAL VALVE INTERVENTIONS

10.4244/EIJV12SYA21 Sep 18, 2016
Intrepid transcatheter mitral valve replacement system: technical and product description
Meredith I et al
free

10.4244/EIJV11SWA22 Sep 17, 2015
The CardiAQ transcatheter mitral valve implantation system
Søndergaard L et al
free

MITRAL VALVE INTERVENTIONS

10.4244/EIJV12SYA22 Sep 18, 2016
HighLife transcatheter mitral valve replacement
Lange R and Piazza N
free

EXPERT REVIEW

10.4244/EIJ-D-17-00673 Sep 24, 2017
Transcatheter mitral valve replacement: device landscape and early results
Patel A and Bapat VN
free

10.4244/EIJV11SWA11 Sep 17, 2015
The MitraClip transcatheter mitral valve repair system
Grasso C and Baldus S
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved